Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 ...

Actress, singer and health advocate Jamie-Lynn Sigler has been entertaining audiences since the age of seven, getting her start in New York regional theater productions. Since that early introduction ...

Morgan Stanley (NYSE:MS) initiated coverage on Novartis (SIX:NOVN:SW) (NYSE: NVS) with an Underweight rating and set a price ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...

The new data presented by Novartis at ECTRIMS 2022 highlighted the safety and efficacy of Kesimpta and supported its use as an early intervention treatment option, as well as demonstrating high ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta.

Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Novartis' research and development focuses on areas of unmet medical need, which should yield several innovative therapies with strong pricing power. The patent loss on multiple sclerosis drug ...